Fund Details
Overview
Investment portfolio
21rounds
| NAME | DATE | SIZE | |
|---|---|---|---|
Leal Therapeutics | Aug 2026Participated | $30 MSeries A | |
Create Medicines | May 2026Led | $122 MSeries B | |
Leal Therapeutics | Aug 2025Participated | $30 MSeries A | |
nChroma Bio | Dec 2024Led | $75 MOther Equity | |
Metsera | Nov 2024Participated | $215 MSeries B | |
Leal Therapeutics | Oct 2024Led | $45 MOther Equity | |
Autobahn Therapeutics | Jul 2024Led | $100 MSeries C | |
Metsera | Apr 2024Participated | $290 MOther Equity | |
Magnet Biomedicine | Sep 2023Led | $50 MSeries A | |
Create Medicines | May 2023Participated | $73 MOther Equity | |
Orbital Therapeutics | Apr 2023Participated | $270 MSeries A | |
Chroma Medicine | Mar 2023Participated | $135 MSeries B | |
Leal Therapeutics | Aug 2026Participated | $30 MSeries A | |
Create Medicines | May 2026Led | $122 MSeries B | |
Leal Therapeutics | Aug 2025Participated | $30 MSeries A | |
nChroma Bio | Dec 2024Led | $75 MOther Equity | |
Metsera | Nov 2024Participated | $215 MSeries B | |
Leal Therapeutics | Oct 2024Led | $45 MOther Equity | |
Autobahn Therapeutics | Jul 2024Led | $100 MSeries C | |
Metsera | Apr 2024Participated | $290 MOther Equity | |
Magnet Biomedicine | Sep 2023Led | $50 MSeries A | |
Create Medicines | May 2023Participated | $73 MOther Equity | |
Orbital Therapeutics | Apr 2023Participated | $270 MSeries A | |
Chroma Medicine | Mar 2023Participated | $135 MSeries B |
21 Items
21
Items
...
Insights
Time horizon
View by
Deal Distribution
| Round type | Led deals | Participated deals |
|---|---|---|
| Series A | 2 | 6 |
| Series B | 1 | 5 |
| Series C+ | 1 | 0 |
| Other Equity | 3 | 3 |
Monthly Deal Activity
| Month | Deals |
|---|---|
| Dec '20 | 1 |
| Jan '21 | 1 |
| Feb '21 | 0 |
| Mar '21 | 0 |
| Apr '21 | 0 |
| May '21 | 0 |
| Jun '21 | 1 |
| Jul '21 | 1 |
| Aug '21 | 0 |
| Sep '21 | 1 |
| Oct '21 | 2 |
| Nov '21 | 1 |
| Dec '21 | 0 |
| Jan '22 | 0 |
| Feb '22 | 0 |
| Mar '22 | 0 |
| Apr '22 | 0 |
| May '22 | 0 |
| Jun '22 | 0 |
| Jul '22 | 0 |
| Aug '22 | 0 |
| Sep '22 | 0 |
| Oct '22 | 1 |
| Nov '22 | 0 |
| Dec '22 | 0 |
| Jan '23 | 0 |
| Feb '23 | 0 |
| Mar '23 | 1 |
| Apr '23 | 1 |
| May '23 | 1 |
| Jun '23 | 0 |
| Jul '23 | 0 |
| Aug '23 | 0 |
| Sep '23 | 1 |
| Oct '23 | 0 |
| Nov '23 | 0 |
| Dec '23 | 0 |
| Jan '24 | 0 |
| Feb '24 | 0 |
| Mar '24 | 0 |
| Apr '24 | 1 |
| May '24 | 0 |
| Jun '24 | 0 |
| Jul '24 | 1 |
| Aug '24 | 0 |
| Sep '24 | 0 |
| Oct '24 | 1 |
| Nov '24 | 1 |
| Dec '24 | 1 |
| Jan '25 | 0 |
| Feb '25 | 0 |
| Mar '25 | 0 |
| Apr '25 | 0 |
| May '25 | 0 |
| Jun '25 | 0 |
| Jul '25 | 0 |
| Aug '25 | 1 |
| Sep '25 | 0 |
| Oct '25 | 0 |
| Nov '25 | 0 |
| Dec '25 | 0 |
| Jan '26 | 0 |
| Feb '26 | 0 |
| Mar '26 | 0 |
| Apr '26 | 0 |
| May '26 | 1 |
| Jun '26 | 0 |
| Jul '26 | 0 |
| Aug '26 | 1 |
| Sep '26 | 0 |
| Oct '26 | 0 |
Sector Breakdown
A deal can appear in multiple sectors, so sector totals may overlap. Capital represents disclosed total round sizes, not fund cheque sizes.
| Sector | Deals |
|---|---|
| Health & Life Sciences | 21 |
| Space & Frontier Tech | 3 |
| Consumer & Lifestyle | 1 |
Deal Size Distribution
Undisclosed round sizes are excluded. Capital represents total round sizes, not fund cheque sizes.
| Round size band (USD) | Deals |
|---|---|
| <$5M | 0 |
| $5M-$10M | 0 |
| $10M-$25M | 1 |
| $25M-$50M | 4 |
| $50M-$100M | 6 |
| $100M-$250M | 7 |
| $250M-$500M | 3 |
| $500M-$1B | 0 |
| $1B+ | 0 |
Deals By Geography
Top 1 of 1 regions; European countries are grouped as Europe.
| Region | Deals |
|---|---|
| United States | 21 |
Co-Investors
Bubble size = shared deals
Click a bubble to open that fund in a new tab.
Shows up to 20 co-investors ranked by shared deals. Deals may be shared with multiple funds, so rows overlap. Capital is total round size, not fund cheque size.
| Co-investor | Shared deals |
|---|---|
| Alexandria Venture Investments | 12 |
| ARCH Venture Partners | 12 |
| Casdin Capital | 6 |
| F-Prime Capital | 5 |
| Google Ventures | 5 |
| Mubadala Capital | 5 |
| Cormorant Asset Management | 4 |
| Invus | 4 |
| Janus Henderson Investors | 4 |
| T. Rowe Price Associates | 4 |
| Wellington Management | 4 |
| Atlas Venture | 3 |
| Chugai Venture Fund | 3 |
| Euclidean Capital | 3 |
| Moore Strategic Ventures | 3 |
| Omega Funds | 3 |
| OrbiMed | 3 |
| PhiFund Ventures | 3 |
| Polaris Partners | 3 |
| Samsara BioCapital | 3 |
Investment Strategy
| Category | Deals (count) | Share (%) |
|---|---|---|
| Led | 7 | 33% |
| Participating | 14 | 67% |
| Category | Deals (count) | Share (%) |
|---|---|---|
| Single-lead | 3 | 43% |
| Co-led | 4 | 57% |